ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
Autore | Tsaioun Katya |
Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
Descrizione fisica | 1 online resource (524 p.) |
Disciplina |
615.19
615/.19 |
Altri autori (Persone) | KatesSteven A |
Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
Record Nr. | UNINA-9910133588303321 |
Tsaioun Katya
![]() |
||
Hoboken, : Wiley, 2012 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
Autore | Tsaioun Katya |
Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
Descrizione fisica | 1 online resource (524 p.) |
Disciplina |
615.19
615/.19 |
Altri autori (Persone) | KatesSteven A |
Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
Record Nr. | UNINA-9910830164603321 |
Tsaioun Katya
![]() |
||
Hoboken, : Wiley, 2012 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
ADMET for Medicinal Chemists [[electronic resource] ] : A Practical Guide |
Autore | Tsaioun Katya |
Pubbl/distr/stampa | Hoboken, : Wiley, 2012 |
Descrizione fisica | 1 online resource (524 p.) |
Disciplina |
615.19
615/.19 |
Altri autori (Persone) | KatesSteven A |
Soggetto topico |
Drug Design
Drug Toxicity Drugs - Testing Drugs --Testing --Juvenile literature Pharmaceutical Preparations - chemistry Pharmacokinetics Metabolic Phenomena Drug Discovery Pharmacological Phenomena Natural Science Disciplines Kinetics Chemicals and Drugs Poisoning Biochemical Phenomena Chemistry, Pharmaceutical Substance-Related Disorders Disciplines and Occupations Investigative Techniques Physiological Phenomena Phenomena and Processes Chemical Phenomena Diseases Pharmacology Analytical, Diagnostic and Therapeutic Techniques and Equipment Biological Science Disciplines Chemistry Pharmaceutical Preparations Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
Record Nr. | UNINA-9910841604803321 |
Tsaioun Katya
![]() |
||
Hoboken, : Wiley, 2012 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances and new perspectives in marine biotechnology Marine animals & plants . Volume 1 [[electronic resource] /] / Paul F. Long, Bernie Degnan and Pabulo H. Rampelotto (Eds.) |
Pubbl/distr/stampa | Basel, Switzerland : , : MDPI AG - Multidisciplinary Digital Publishing Institute, , 2015 |
Descrizione fisica | 1 online resource (xvii, 407 pages) : illustrations (black & white, some colour); digital, PDF file(s) |
Disciplina | 591.77 |
Collana | Advances and new perspectives in marine biotechnology |
Soggetto topico |
Marine biotechnology
Marine animals Marine microbiology - Research Biomedical materials Drug Discovery |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910131416303321 |
Basel, Switzerland : , : MDPI AG - Multidisciplinary Digital Publishing Institute, , 2015 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Advances and new perspectives in marine biotechnology Marine animals & plants . Volume 1 [[electronic resource] /] / Paul F. Long, Bernie Degnan and Pabulo H. Rampelotto (Eds.) |
Pubbl/distr/stampa | Basel, Switzerland : , : MDPI AG - Multidisciplinary Digital Publishing Institute, , 2015 |
Descrizione fisica | 1 online resource (xvii, 407 pages) : illustrations (black & white, some colour); digital, PDF file(s) |
Disciplina | 591.77 |
Collana | Advances and new perspectives in marine biotechnology |
Soggetto topico |
Marine biotechnology
Marine animals Marine microbiology - Research Biomedical materials Drug Discovery |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910674361603321 |
Basel, Switzerland : , : MDPI AG - Multidisciplinary Digital Publishing Institute, , 2015 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Animal models for human cancer : discovery and development of novel therapeutics / / edited by Marianne I. Martic-Kehl and P. August Schubiger |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , 2016 |
Descrizione fisica | 1 online resource (313 p.) |
Disciplina | 616.994027 |
Collana | Methods and Principles in Medicinal Chemistry |
Soggetto topico |
Cancer - Animal models
Disease Models, Animal Neoplasms, Experimental Drug Discovery Animal Experimentation - ethics |
Soggetto genere / forma | Electronic books. |
ISBN |
3-527-69591-5
3-527-69588-5 3-527-69589-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910166638803321 |
Weinheim, Germany : , : Wiley-VCH, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Animal models for human cancer : discovery and development of novel therapeutics / / edited by Marianne I. Martic-Kehl and P. August Schubiger |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Weinheim, Germany : , : Wiley-VCH, , 2016 |
Descrizione fisica | 1 online resource (313 p.) |
Disciplina | 616.994027 |
Collana | Methods and Principles in Medicinal Chemistry |
Soggetto topico |
Cancer - Animal models
Disease Models, Animal Neoplasms, Experimental Drug Discovery Animal Experimentation - ethics |
ISBN |
3-527-69591-5
3-527-69588-5 3-527-69589-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910830049203321 |
Weinheim, Germany : , : Wiley-VCH, , 2016 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
Autore | Kazmierski Wieslaw M |
Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
Descrizione fisica | 1 online resource (470 p.) |
Disciplina | 615/.7924 |
Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
Record Nr. | UNINA-9910139613803321 |
Kazmierski Wieslaw M
![]() |
||
Hoboken, : Wiley, 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
Autore | Kazmierski Wieslaw M |
Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
Descrizione fisica | 1 online resource (470 p.) |
Disciplina | 615/.7924 |
Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
Record Nr. | UNINA-9910808713803321 |
Kazmierski Wieslaw M
![]() |
||
Hoboken, : Wiley, 2011 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Biomolecular and bioanalytical techniques : theory, methodology and applications / / edited by Vasudevan Ramesh, School of Chemistry, University of Manchester, Manchester,U.K |
Edizione | [1st edition] |
Pubbl/distr/stampa | Hoboken, NJ : , : Wiley, , 2019 |
Descrizione fisica | 1 online resource (579 pages) |
Disciplina | 572.8/38 |
Soggetto topico |
Molecular biology - Technique
Biophysics Medical Informatics Biomedical Technology Cheminformatics Drug Discovery |
ISBN |
1-119-48401-4
1-119-48397-2 1-119-48398-0 |
Classificazione | 464.1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Principles of health and safety and good laboratory practice -- Applications of chemoinformatics in drug discovery -- Bioinformatics and its applications in genomics -- Gene cloning for the analysis of gene expression -- Proteomic techniques and their applications -- Overproduction,separation and purification of affinity-tagged proteins from escherichia coli -- Chromatography: separation techniques in biology -- Synthetic methodology in chemical biology -- Reaction chemical kinetics in biology -- Mass spectrometry and its applications -- Applications and complementarity of analytical ultracentrifugation and light-scattering techniques -- Application of isothermal titration calorimetry (ITC) to biomolecular interactions -- An introduction to infrared and raman spectroscopies for pharmaceutical and biomedical studies -- Fluorescence spectroscopy and its applications in analyzing biomolecular processes -- Circular dichroism and related spectroscopic techniques -- Principles and practice in macromolecular X-ray crystallography -- Biomolecular NMR spectroscopy and structure determination of DNA -- Cryo-TEM and biological structure determination -- Computer modelling and molecular dynamics simulation of biomolecules. |
Record Nr. | UNINA-9910677409503321 |
Hoboken, NJ : , : Wiley, , 2019 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|